My PCR
Create Account
Logo PCR

17 Nov 2025

Tricuspid / Pulmonary valve

Tricuspid interventions: knowns and unknowns

With the collaboration of the PCR Tricuspid Focus Group

Anchorperson: L. Stolz
Spokesperson: J. Hausleiter
SHOW MORE

Summary

Explore the evolving landscape of transcatheter tricuspid valve interventions in this session, which presents the latest evidence from registries and randomized trials. Discussions include the new Euro tricuspid regurgitation risk score, clinical controversies, real-world patient scenarios, and insights into optimal medical therapy and device selection to inform clinical decision-making in this advancing field.

Learning Objectives

  • To hear the latest evidence from registries and randomised controlled trials in the field of transcatheter tricuspid valve intervention
  • To learn more about the new Euro tricuspid regurgitation risk score
  • To discuss the principal controversies in this rapidly advancing domain

Presentations available when logged in:

  • Latest evidence for transcatheter tricuspid valve intervention: an update from current randomised controlled trials
  • The real world - a T-TEER patient ineligible for trial recruitment
  • Does optimal medical therapy exist for patients with tricuspid regurgitation?
  • Should we use transcatheter tricuspid valve replacement in patients with straightforward anatomy who are eligible for T-TEER?
  • Can we summarise all the relevant risk factors for patients with tricuspid regurgitation in a comprehensive score?
  • Case resolution and clinical outcome
Related Content
PCR London Valves 2025: Best of Social Media Coverage Transcatheter tricuspid valve replacement - Part 3 Complex combined transcatheter interventions
Recommended for you
Key updates in valvular heart disease management: insights from the 2025 ESC/EACTS Guidelines Take the stage at EuroPCR PCR Tokyo Valves 2026: What's on the Programme?